South Korea · Delayed Price · Currency is KRW L&K Biomed Statistics
Total Valuation
L&K Biomed has a market cap or net worth of KRW 121.81 billion. The enterprise value is 122.59 billion.
| Market Cap | 121.81B |
| Enterprise Value | 122.59B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
L&K Biomed has 22.35 million shares outstanding. The number of shares has decreased by -1.08% in one year.
| Current Share Class | 22.35M |
| Shares Outstanding | 22.35M |
| Shares Change (YoY) | -1.08% |
| Shares Change (QoQ) | +0.39% |
| Owned by Insiders (%) | 12.01% |
| Owned by Institutions (%) | 0.31% |
| Float | 19.67M |
Valuation Ratios
The trailing PE ratio is 42.39.
| PE Ratio | 42.39 |
| Forward PE | n/a |
| PS Ratio | 3.05 |
| PB Ratio | 2.15 |
| P/TBV Ratio | 1.95 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 44.32 |
| EV / Sales | 3.07 |
| EV / EBITDA | 40.81 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.89, with a Debt / Equity ratio of 0.52.
| Current Ratio | 1.89 |
| Quick Ratio | 1.03 |
| Debt / Equity | 0.52 |
| Debt / EBITDA | 9.12 |
| Debt / FCF | -3.07 |
| Interest Coverage | 0.11 |
Financial Efficiency
Return on equity (ROE) is 4.54% and return on invested capital (ROIC) is 0.58%.
| Return on Equity (ROE) | 4.54% |
| Return on Assets (ROA) | 0.22% |
| Return on Invested Capital (ROIC) | 0.58% |
| Return on Capital Employed (ROCE) | 0.53% |
| Weighted Average Cost of Capital (WACC) | 8.36% |
| Revenue Per Employee | 380.40M |
| Profits Per Employee | 26.34M |
| Employee Count | 105 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 0.20 |
Taxes
| Income Tax | -313.10M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.93% in the last 52 weeks. The beta is 0.76, so L&K Biomed's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | -37.93% |
| 50-Day Moving Average | 4,178.50 |
| 200-Day Moving Average | 8,433.00 |
| Relative Strength Index (RSI) | 69.42 |
| Average Volume (20 Days) | 177,873 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, L&K Biomed had revenue of KRW 39.94 billion and earned 2.77 billion in profits. Earnings per share was 128.57.
| Revenue | 39.94B |
| Gross Profit | 33.18B |
| Operating Income | 338.96M |
| Pretax Income | 1.81B |
| Net Income | 2.77B |
| EBITDA | 3.20B |
| EBIT | 338.96M |
| Earnings Per Share (EPS) | 128.57 |
Balance Sheet
The company has 21.25 billion in cash and 29.22 billion in debt, with a net cash position of -7.97 billion or -356.47 per share.
| Cash & Cash Equivalents | 21.25B |
| Total Debt | 29.22B |
| Net Cash | -7.97B |
| Net Cash Per Share | -356.47 |
| Equity (Book Value) | 56.54B |
| Book Value Per Share | 2,851.76 |
| Working Capital | 41.16B |
Cash Flow
In the last 12 months, operating cash flow was -4.60 billion and capital expenditures -4.92 billion, giving a free cash flow of -9.52 billion.
| Operating Cash Flow | -4.60B |
| Capital Expenditures | -4.92B |
| Depreciation & Amortization | 2.86B |
| Net Borrowing | 25.56B |
| Free Cash Flow | -9.52B |
| FCF Per Share | -425.79 |
Margins
Gross margin is 83.08%, with operating and profit margins of 0.85% and 6.93%.
| Gross Margin | 83.08% |
| Operating Margin | 0.85% |
| Pretax Margin | 4.54% |
| Profit Margin | 6.93% |
| EBITDA Margin | 8.02% |
| EBIT Margin | 0.85% |
| FCF Margin | n/a |
Dividends & Yields
L&K Biomed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.08% |
| Shareholder Yield | 1.08% |
| Earnings Yield | 2.27% |
| FCF Yield | -7.81% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
L&K Biomed has an Altman Z-Score of 2.72 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.72 |
| Piotroski F-Score | 5 |